Document Detail

Efficacy and safety of Jentadueto® (linagliptin plus metformin).
MedLine Citation:
PMID:  23421949     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Metformin is the first-choice drug in the management of type 2 diabetes. However, most patients require a combined therapy to reach and/or maintain targets of glucose control. Dipeptidyl peptidase-4 (DPP-4) inhibitors offer new options for combined therapy with metformin. Linagliptin shares a similar pharmacodynamic (PD) profile with other gliptins, but has a unique pharmacokinetic (PK) profile characterized by negligible renal excretion.
AREAS COVERED: An extensive literature search was performed to analyze the potential PK/PD interactions between linagliptin and metformin. They are not prone to PK drug-drug interactions. The two compounds may be administered together, either separately or using a fixed-dose combination (FDC) as shown by bioequivalence studies. The addition of linagliptin in patients not well controlled with metformin alone has proven its efficacy in improving glucose levels with a good safety profile. Initial co-administration of linagliptin plus metformin improves glucose control more potently than either compound separately, without hypoglycemia, weight gain or increased metformin-related gastrointestinal side effects.
EXPERT OPINION: The linagliptin plus metformin combination may offer some advantages over the classical sulfonylurea-metformin combination. Even if linagliptin is safe in patients with renal impairment, the use of metformin (and thus of the linagliptin plus metformin FDC) is still controversial in this population.
André J Scheen
Related Documents :
25083209 - New generation antiepileptic drugs: what do they offer in terms of improved tolerabilit...
7086659 - Conductivity studies of suspension systems in different states of aggregation.
25043209 - Association between baseline pulmonary status and interstitial lung disease in patients...
2723109 - Correction of blood drug levels for changes over the day.
24691829 - Effect of sophora flavescens on the pharmacokinetics of carbamazepine in rats.
18606399 - Pharmacological effects of a novel isosorbide-based butyrylcholinesterase inhibitor.
15767019 - Direct t-cell stimulations by drugs--bypassing the innate immune system.
19381829 - Formulation and performance characterization of radio-sterilized "progestin-only" micro...
25083209 - New generation antiepileptic drugs: what do they offer in terms of improved tolerabilit...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  12     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-20     Completed Date:  2013-10-31     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  275-89     Citation Subset:  IM    
University of Liège, Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart-Tilman (B35), B-4000 Liège 1, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Diabetes Mellitus, Type 2 / blood,  drug therapy*
Drug Combinations
Hypoglycemic Agents / administration & dosage,  adverse effects
Metformin / administration & dosage*,  adverse effects*
Purines / administration & dosage*,  adverse effects*
Quinazolines / administration & dosage*,  adverse effects*
Randomized Controlled Trials as Topic / methods
Treatment Outcome
Reg. No./Substance:
0/Drug Combinations; 0/Hypoglycemic Agents; 0/Purines; 0/Quinazolines; 3X29ZEJ4R2/Linagliptin; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Medication wrong route administration: a poisons center-based study.
Next Document:  Conductance Modulation in Tetraaniline Monolayers by HCl-Doping and by Field-Enhanced Dissociation o...